Serum cytokine profiling reveals CXCL10 (IP-10) as a major predictor of severe COVID-19 outcomes in hospitalized patients during the first pandemic wave in Italy - Takeaways - MDSpire

Serum cytokine profiling reveals CXCL10 (IP-10) as a major predictor of severe COVID-19 outcomes in hospitalized patients during the first pandemic wave in Italy

  • By

  • Anita Muglia

  • Daniele Petrone

  • Ilaria Schiavoni

  • Letizia Santinelli

  • Pasqualina Leone

  • Antonino Bella

  • Gabriella d’Ettorre

  • Francesco Alessandri

  • Anna Teresa Palamara

  • Claudio Maria Mastroianni

  • Paola Stefanelli

  • Giorgio Fedele

  • May 25, 2026

  • 0 min

Share

  • 1

    CXCL10 was identified as the strongest predictor of adverse outcomes in hospitalized COVID-19 patients during Italy's first pandemic wave.

  • 2

    Each 1,000 pg/mL increase in CXCL10 was associated with increased odds of death, ICU admission, and composite outcomes.

  • 3

    The study included 103 RT-PCR-confirmed COVID-19 patients, with ICU admission at 6.8% and mortality at 11.7%.

  • 4

    Other inflammatory mediators like TNF-α showed trends toward association with ICU admission, while IL-6 was not significant.

  • 5

    The findings suggest that integrating CXCL10 levels with clinical parameters may enhance risk stratification in COVID-19.

Original Source(s)

Serum cytokine profiling reveals CXCL10 (IP-10) as a major predictor of severe COVID-19 outcomes in hospitalized patients during the first pandemic wave in Italy

  • by Anita Muglia, Daniele Petrone, Ilaria Schiavoni, Letizia Santinelli, Pasqualina Leone, Antonino Bella, Gabriella d’Ettorre, Francesco Alessandri, Anna Teresa Palamara, Claudio Maria Mastroianni, Paola Stefanelli, Giorgio Fedele

  • May 25, 2026

Related Content

Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.